期刊
CLINICAL INFECTIOUS DISEASES
卷 55, 期 -, 页码 S49-S53出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis363
关键词
-
资金
- Abbott Laboratories
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Genentech (Roche)
- Gilead Sciences
- GlaxoSmithKline
- Janssen Therapeutics
- Merck Sharp Dohme
- OraSure Technologies
- Vertex Pharmaceuticals
- Viral Hepatitis Action Coalition of the CDC Foundation
Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing and treatment, and the prospect of increasing incidence associated with the epidemic of injection drug use. Three-quarters of chronic HCV infections occur among persons born from 1945 through 1965. Prevention efforts are complicated by limited knowledge among health care professionals, persons at risk and in the public at large. At the Centers for Disease Control and Prevention, efforts to improve primary and secondary prevention effectiveness center on policy development, education and training initiatives, and applied research. This report provides a brief overview of some of these efforts, including the development of testing recommendations for the 1945-1965 birth cohort, research and evaluation studies in settings where persons who inject drugs receive services, and a national viral hepatitis education campaign that targets health care professionals, the public, and persons at risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据